drugset / Trial / NCT07230626
SYS6002 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a randomized, open-label, controlled, multicenter phase Ⅲ clinical trial, which aims to evaluate the efficacy and safety of SYS6002 versus investigator's choice of chemotherapy in the treatment of participants with recurrent or metastatic cervical cancer who have failed platinum-containing chemotherapy and PD-1/L1 inhibitor therapy
Timeline
- Start
- 2025-11-20
- Primary completion
- 2028-01-01
- Completion
- 2028-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Comparator | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Comparator | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |
| Subject | SYS6002 | Other / unclassified | — | Intravenous |
| Comparator | Topotecan | Small molecule | 1.2 mg/m2 | Intravenous |